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A potent anti-West Nile virus (anti-WNV)-neutralizing humanized monoclonal antibody, hE16, was
previously shown to improve the survival of WNV-infected hamsters when it was administered intraperi-
toneally (i.p.), even after the virus had infected neurons in the brain. In this study, we evaluated the
therapeutic limit of hE16 for the treatment of WNV infection in hamsters by comparing single-dose
peripheral (i.p.) therapy with direct administration into the pons through a convection-enhanced delivery
(CED) system. At day 5 after infection, treatments with hE16 by the peripheral and the CED routes were
equally effective at reducing morbidity and mortality. In contrast, at day 6 only the treatment by the CED
route protected the hamsters from lethal infection. These experiments suggest that hE16 can directly
control WNV infection in the central nervous system. In support of this, hE16 administered i.p. was
detected in a time-dependent manner in the serum, cerebrospinal fluid (CSF), cerebral cortex, brain stem,
and spinal cord in CSF. A linear relationship between the hE16 dose and the concentration in serum was
observed, and maximal therapeutic activity occurred at doses of 0.32 mg/kg of body weight or higher, which
produced serum hE16 concentrations of 1.3 g/ml or higher. Overall, these data suggest that in hamsters
hE16 can ameliorate neurological disease after significant viral replication has occurred, although there
is a time window that limits therapeutic efficacy.
Since patients infected with West Nile virus (WNV) often
present for medical attention with symptoms that suggest
possible central nervous system (CNS) infection (9), thera-
pies for WNV neurological disease should work even after
the virus has infected the CNS. One possible therapy, im-
mune immunoglobulin G (IgG), is being evaluated in a
phase IIB clinical trial (NIH identifier NCT00068055) that
assesses safety and efficacy in patients with known or sus-
pected WNV infection. However, the product (Omr-Ig-
Gam) was generated from pools of nonimmune and immune
serum from Israeli donors and has a relatively low neutral-
izing activity against the strains of WNV that currently cir-
culate in North America (2, 6).
A mouse monoclonal antibody (MAb), E16, specific for do-
main III (DIII) of the envelope protein, has been identified to
have potent WNV-neutralizing activity (7, 19, 20). This MAb
engaged 16 residues positioned on four loops of DIII and
formed a consensus neutralizing epitope in virtually all WNV
strains tested (18). Structural and virological studies suggest
that E16 blocks infection at a postattachment state, possibly by
inhibiting virus-endosome fusion and nucleocapsid release into
the cytoplasm (18). A humanized version of E16 (hE16) that
retained its antigen specificity, avidity, and neutralizing activity
was generated. Studies with mice showed that treatment was
effective even at 5 days after viral injection (16, 19), a time at
which infectious virus was identified in homogenized mouse
brain.
Studies with a hamster model of WNV infection subse-
quently confirmed that hE16 is effective after the virus had
infected neurons in the CNS (16). This conclusion was based
on the observation that WNV RNA and WNV antigen-positive
neurons were present in the brain when hE16 was adminis-
tered intraperitoneally (i.p.) at 5 days after infection. More-
over, individual hamsters with WNV in their cerebrospinal
fluid (CSF) at 5 days postinfection (dpi) were protected from
death by hE16 treatment on that day. The goals of the current
study were (i) to determine how long hE16 systemic or intra-
cerebral treatment could be delayed without losing efficacy, (ii)
to define the effective dose limit of hE16, (ii) to measure the
serum and CSF concentrations of hE16 at various time points
after administration, (iv) to assess the concentration of hE16 in
homogenized neurological tissues, and (v) to establish the tim-
ing of hE16 treatment in relation to the endogenous produc-
tion of WNV-neutralizing antibody in the serum and CSF. Our
studies suggest that hE16 in the CNS ameliorates neurological
disease after significant viral replication has occurred. In the
hamster, a survival benefit is gained up through day 6 after
infection.
* Corresponding author. Mailing address: Institute for Antiviral Re-
search, Animal, Dairy, and Veterinary Sciences Department, Utah
State University, 4700 Old Main Hill, Logan, UT 84322-4700. Phone:
(435) 797-2622. Fax: (435) 797-2766. E-mail: jmorrey@cc.usu.edu.
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Animals and virus. Adult female Syrian golden hamsters (Charles River Lab-
oratories) greater than 7 weeks of age were used. The animals were randomized
to treatment groups. Animal use was in compliance with the Utah State Univer-
sity Institutional Animal Care and Use Committee, and the animals were kept in
an AAALAC-accredited facility. Prototypic WNV strain NY99 (11, 12) was
propagated in MA-104 cells and diluted appropriately in minimal essential me-
dium immediately prior to injection.
Antibody. The humanized MAb (IgG1) specific for WNV (MAb hE16) (16,
19) was obtained from MacroGenics, Inc. (Rockville, MD). Upon arrival, the
material was immediately stored in a refrigerator. Palivizumab (Synagis;
MedImmune, Gaithersburg, MD), a humanized IgG1 MAb used to prevent
respiratory syncytial virus disease in at-risk infants, was used as a control.
Collection of CSF from hamsters. CSF was collected from the cisterna magna
of live hamsters (16). The animals were anesthetized with ketamine HCl and
placed in a stereotaxic device (David Kopf Instruments, Tujunga, CA) with the
neck maximally flexed to fully expose the atlanto-occipital fossa. Anesthesia was
maintained through the remainder of the procedure by the use of isoflurane
inhalation (2% isoflurane, 1 liter O2/min). A 5- to 7-mm incision was made from
the shoulders to the dorsal aspect of the skull. CSF was collected with a 30-gauge
needle attached to one end of a short length of Tygon microbore tubing (inner
diameter, 0.01 in.; Saint-Gobain Corporation, Valley Forge, PA) and with a
syringe attached to the other end. The needle in the arm of the stereotaxic device
was inserted into the neck 4 mm ventral of the crest of the skull and on the
midline. With the maintenance of mild suction with the syringe, the needle was
slowly advanced until fluid was observed to be entering the tube. CSF (30 to 70
l) was collected from each animal. Red blood cells were counted to determine
the extent of blood contamination and to eliminate contaminated CSF from the
data set.
Implantation of cannula into the pons. Anesthesia was induced by the i.p.
administration of ketamine-HCl at a dose of 100 mg/kg of body weight and was
maintained through the duration of the procedure by using isoflurane inhalation
anesthesia (2% isoflurane, 1 liter O2/min) (16). After shearing and disinfection
of the surgical site, the animals were placed in the stereotaxic device (David Kopf
Instruments). All measurements for placement of the cannula used the bregma
as a reference point. For placement in the caudal pontine reticular nucleus, a
hole 1.2 mm mediolateral and 5.2 mm anterior-posterior was drilled for
placement of a cannula into the parenchyma of the pontine region of the pons,
according to the indications of a hamster stereotaxic atlas (15). A custom-
designed cannula (Plasatic One Inc., Roanoke, VA) with a preset depth of 7 mm
from the skull surface was inserted into the hole and secured in place with tissue
glue (Vetbond tissue adhesive; 3M Company, St. Paul, MN). An Alzet osmotic
pump (Durect Corporation, Cupertino, CA) was attached to the cannula with a
short plastic tube, and the osmotic pump was placed subcutaneously over the
shoulder region of the animal. The surgical incision was closed with nylon suture.
The animal was administered a single subcutaneous (s.c.) dose of buprenorphine
analgesic (0.10 mg/kg) and allowed to recover from anesthesia. In previous
experiments, the functionality of the osmotic pumps was verified by injecting a
waterproof dye into the cannula to verify the location of the cannula. An osmotic
pump (catalog no. 2001D) was loaded with 200 l of MAb hE16 at a concen-
tration of 26 mg/ml; the pump delivers 8 l/h or 5 mg/hamster over the course of
24 h. The pump was predicted to last only 1 day.
Viral assays. Quantitative reverse transcriptase PCR (RT-PCR) was used to
determine the number of WNV RNA genomes present in the fluid extracted
from cells, as reported previously (10, 16, 25). Serum or CSF was added to
TRIzol RNA purification reagent (Sigma-Aldrich Chemical), and linear acryl-
amide (10 to 20 ng; Ambion) and total normal mouse RNA (10 g) were added
as carriers. The RNA was purified with the TRIzol reagent (Invitrogen) and used
in the RT-PCRs. Primer pair TCAGCGATCTCTCCACCAAAG (forward
primer) and GGGTCAGCACGTTTGTCATTG (reverse primer) and the Taq-
Man probe (5–6-carboxyfluorescein–TGCCCGACCATGGGAGAAGCTC–6-c
arboxy-N,N,N,N-tetramethylrhodamine–3; QIAGEN, Valencia, CA) were
used. Mouse glyceraldehyde phosphate dehydrogenase (mGAPDH) was de-
tected by using primer pair GTTACCAGGGCTGCCTTCTC (forward primer)
and GGGTTTCCCGTTGATGACC (reverse primer) and the TaqMan probe
(5–hexachlorofluorescein–AACGGCACAGTCAAGGCTGAGAATG–BHQ-5)
(26). The one-step FullVelocity quantitative RT-PCR master mix (Stratagene,
La Jolla, CA) was used for reverse transcription and the amplification of WNV
and mGAPDH RNA in a duplex reaction. Samples were run on a DNA Engine
Opticon 2 apparatus (MJ Research Inc, Waltham, MA). Reverse transcription of
the RNA was performed for 30 min at 50°C, followed by PCR, which consisted
of 30 cycles of 15 s at 95°C and 60 s at 61°C. Control WNV RNA transcripts were
obtained from an in vitro transcription reaction of the cloned PCR product in a
linearized plasmid. The mean threshold cycle value for each sample was used to
obtain the WNV RNA values by using a standard curve. The data are reported
as WNV genome equivalents/ml for serum or CSF samples and WNV transcript
equivalents/gram for all other tissues.
WNV plaque assay. The neutralizing activities of serum or CSF antibodies
were determined by a plaque reduction assay (13). After incubation at 56°C,
serial dilutions of the serum or CSF samples were mixed and incubated with
stock WNV (100 PFU). A volume of 50 l was added to each well of a six-well
plate, and the plate was incubated for 1 h with periodic rocking. A 2-ml agarose
overlay was added. Four days later, the cells were stained with neutral red vital
stain and the plaques were counted. The inverse of the dilution that caused a
90% reduction was reported as the plaque reduction neutralization titer. The
titer of infectious virus was similarly determined, except that no serum was added
to the sample. Serial dilutions of stock virus in the assay were used to calculate
the numbers of PFU per gram of tissue or ml of serum or CSF.
Detection of MAb hE16. The MAb hE16 concentrations in hamster serum or
CSF were determined by enzyme-linked immunosorbent assay (16). Dilutions of
serum were incubated in wells coated with 100 ng goat anti-human IgG (Fc
specific; Jackson ImmunoResearch Laboratories). After incubation and washing
of the plates, bound hE16 was detected with alkaline phosphatase-conjugated
goat anti-human kappa chain (dilution, 1/10,000; Jackson) and then developed by
using the fluorogenic substrate 4-methylumbelliferyl phosphate (Sigma). The
plates were then read with a fluorometric plate reader, and the concentrations
were calculated from a standard curve by using a nonlinear four-parameter fit.
The limit of detection of hE16 in serum or CSF was 0.06 g/ml.
Statistical analysis. Survival data were analyzed by log rank survival analysis
(JMP software, the Statistical Discovery software; SAS Institute, Inc).
RESULTS
Treatment delay limitations. To determine how long hE16
treatment could be delayed without losing efficacy, hamsters
that had been challenged s.c. with WNV were treated with
MAb hE16, which was delivered either by i.p. injection or by
use of a convection-enhanced delivery (CED) system (Fig. 1).
As observed previously (16), hE16 is effective in preventing
death when a single 32-mg/kg dose is administered i.p. at 5 dpi,
a time when WNV had already infected CNS neurons (P 
0.01) (Fig. 1D). Efficacy was lost if the administration of hE16
by i.p. injection was delayed until 6 dpi (Fig. 1E), at which time
the survival curves were essentially the same as those for
vehicle-treated animals. Likewise, hE16 administration by the
CED route was effective when treatment was initiated at 5 dpi
(P  0.01). In contrast, treatment by the CED route was also
effective if it was initiated at 6 dpi (P  0.01) (Fig. 1A and B).
However, treatment with hE16 by the CED route was not
effective if it was initiated at 8 dpi (Fig. 1C).
Timing of hE16 treatment with virus infection and produc-
tion of antibody. To better understand the relationship be-
tween the emergence of endogenously produced WNV-specific
antibody, virus infection, and the timing of effective hE16
treatment, neutralizing antibody and WNV titers were mea-
sured in the serum and CSF of untreated, WNV-infected ham-
sters over time. Infectious virus was detected in serum by viral
plaque assay beginning at day 2, and the virus levels decreased
thereafter through day 5; infectious virus was no longer de-
tected at day 6 after infection (Fig. 2A). On the basis of the
findings from studies with mice (5), we postulated that virus
reductions in serum should coincide with the appearance and
accumulation of WNV-neutralizing antibody. Indeed, begin-
ning on day 4 (Fig. 2B), we detected significant amounts of
neutralizing antibody in the sera of some hamsters. Infectious
virus was detected in the CSF on days 4 and 5 after infection
(Fig. 2C), and WNV RNA was observed between days 3 and 6
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(Fig. 2D). Presumably, since RT-PCR detects both viable and
nonviable virus and the plaque assay detects viable virus, the
virus was more detectable by the RT-PCR assay. The levels of
infectious virus or viral RNA in the CSF declined significantly
on day 6. Overall, there was an 2-day lag in the appearance
of WNV in the CSF compared to the time of appearance of
WNV in serum. The decline in WNV levels in the CSF also
correlated with the appearance of detectable levels of neutral-
izing antibody in the CSF (Fig. 2E).
Effective dose and serum concentrations of MAb hE16. To
determine an effective dose for MAb hE16 treatment at 5
days after infection, a dose-response analysis was per-
formed. Serial dilutions of hE16 (100 to 0.32 mg/kg) were
administered to the hamsters i.p. at 5 days after infection
and survival was monitored. The maximal percent survival
(80%) occurred with a dose of 3.2, 10, or 32 mg/kg; the rate
of survival was 67% with a dose of 0.32 or 1 mg/kg, and the
rate of survival was 33% for the saline control group (data
not shown).
Since significant protection was still observed at the low-
est dose tested (0.32 mg/kg), the experiment was repeated
with doses as low as 0.010 mg/kg. The percent survival was
plotted against the MAb hE16 dose (Fig. 3A). The maximal
percent survival (62.5%) was observed at doses of 0.32, 1.0,
and 100 mg/kg. The percent survival for the saline control
group was 0%. By using linear regression to fit an equation
to a line, half of the maximum effective dose (MED50) of
hE16 was calculated to be 0.13 mg/kg (Fig. 3A). The serum
hE16 levels measured 1 day after i.p. injection correlated
linearly (R2  0.99) with the hE16 dose administered (Fig.
3B). On the basis of this result, the half-maximal effective
concentration (MEC50) of hE16 in serum is 0.44 g/ml. A
plot of the percent survival against the serum hE16 concen-
tration demonstrates that maximal therapeutic efficacy oc-
FIG. 1. Efficacy of humanized MAb hE16 when it is delivered i.p. or by the CED route to hamsters infected with WNV by the s.c. route. Artif.
CSF, artificial CSF (solution of sodium, potassium calcium, and magnesium in CSF) (16). (A) Eight and nine animals were used in the hE16- and
placebo-treated groups, respectively. The animals were infected with 105.3 50% cell culture infectious doses of WNV (17). hE16 (5 mg/hamster/day,
43 mg/kg/day, 116 g/hamster) was administered by the CED route. (B) Twelve animals were used in each group, and the animals were infected
with 107.1 50% cell culture infectious doses of WNV. hE16 (5 mg/hamster/day, 31 mg/kg/day, 160 g/hamster) was administered by the CED route.
(C) Ten and nine animals were used in the hE16- and placebo-treated groups, respectively. The animals were infected with 107.1 50% cell culture
infectious doses of WNV. hE16 (5 mg/hamster, 48 mg/kg/day, 103 g/hamster) was administered by the CED route. (D) Ten animals were used in
each group, and the animals were infected with 105.7 50% cell culture infectious doses of WNV. hE16 (32 mg/kg) was administered i.p. (E) Thirty
animals were used in each group, and the animals were infected with 107.1 50% cell culture infectious doses of WNV. hE16 (32 mg/kg) was
administered i.p. **, P  0.01 by log rank survival analysis.
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curs with serum hE16 concentrations 1.2 g/ml or higher
(Fig. 3C).
Serum and CSF MAb hE16 concentrations over time. To
better understand the pharmacokinetics of antibody accumu-
lation and/or consumption, we measured the concentrations of
MAb hE16 in the serum and CSF of WNV-infected or sham-
infected hamsters at 7, 12, and 30 dpi after treatment with a
single i.p. injection of hE16 (32 mg/kg) at 5 dpi. Interestingly,
although the concentrations of hE16 in serum (Fig. 4A) and
CSF (Fig. 4B) declined over time, there was no statistically
significant difference between the results for the WNV- and
sham-infected hamsters. Even at day 30 postinfection, hE16
was detectable in all 15 serum samples (concentration range,
13.4 to 35.9 g/ml) and in 7 of 15 CSF samples (concentration
range, 0.07 to 0.15 g/ml). However, hE16 penetration into the
CSF was relatively poor, as the mean concentrations of hE16 in
serum were 330- to 630-fold higher than those in CSF at each
of the three time points at which they were tested. Nonethe-
less, because the concentrations of hE16 in serum and CSF
were not significantly different between uninfected and in-
fected animals, the majority of the antiviral antibody remains
circulating and is not sequestered by phagocytic cells as virus-
immune complexes.
MAb hE16 concentrations in neurological tissues. We as-
sessed the MAb hE16 levels in tissue homogenates to deter-
mine if the levels in serum were a reliable indicator of the hE16
concentration in other relevant CNS tissues (Fig. 5). In ham-
sters treated with 32 mg/kg hE16 i.p. at 5 dpi, the hE16 con-
centrations in serum at 7 dpi correlated with the hE16 levels in
CNS tissues and CSF at 7 dpi. Data from the WNV-infected
and sham-infected hamsters were combined, because there
were no statistically significant differences in the tissue hE16
concentrations between the groups (data not shown). There
was a generally linear trend between increased serum and
tissue hE16 levels, as the R2 values between the levels in serum
and the levels in CSF, cerebral cortex, brain stem, and thoracic/
lumbar spinal cord were 0.47, 0.45, 0.57, and 0.17, respectively.
Thus, with the exception of the thoracic/lumbar spinal cord,
the serum concentrations of hE16 were indicators of other
neurological tissue concentrations.
DISCUSSION
As established previously (16), MAb hE16 administered i.p.
as a single injection at 5 dpi improved the survival of hamsters
infected s.c. with WNV. In this study, we demonstrated that
when hE16 treatment i.p. was delayed to day 6, it was no longer
effective at reducing mortality. In contrast, if hE16 was directly
administered into the pons of the brain by the CED route at
day 6, it enhanced survival. CED administration was not per-
formed with the anticipation that it might be eventually used in
human patients. It was designed to show that hE16, in part,
acts directly in the CNS to prevent neuronal infection and
injury.
Our pharmacokinetic analyses demonstrate that the CSF
MAb hE16 concentrations were approximately 500-fold lower
than the serum hE16 concentrations. Similarly low CSF con-
centration/serum concentration ratios have been observed for
other peripherally administered MAbs in mice, rats, and hu-
mans (1, 8, 14, 21, 23, 24). Despite encephalitis and CNS
inflammation in the hamsters, only a small fraction of the
peripherally administered hE16 efficiently crosses the blood-
brain barrier and inhibits and/or controls infection. The CED
route of administration, however, enhanced the hE16 levels in
the brain and, accordingly, extended the therapeutic window
by at least 1 day. Nonetheless, the delivery of hE16 directly into
the brain by the CED route at day 8 after WNV infection did
not reverse the course of disease, as no survival benefit was
observed. We speculate that this limit was due to the over-
whelming infection of neurons that was not reversed by hE16
treatment, irreversible neuronal injury that had occurred prior
to therapeutic intervention, or theoretically, the emergence of
FIG. 2. Temporal expression of WNV and neutralizing antibody in serum and CSF of hamsters infected s.c. with 105.3 50% cell culture
infectious doses of WNV. PRNT, plaque reduction neutralization test for measurement of neutralizing antibody; dashed lines, limit of detection.
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escape variants that were not neutralized by hE16. However,
for unclear reasons, despite the sequencing of over 30 inde-
pendent isolates from the brains of E16-treated WNV-infected
moribund mice, we have been unable to identify a single virus
that had mutations at any of the E16 contact residues, as
defined by X-ray crystallography (T. Oliphant and M. S.
Diamond, unpublished data).
The latest time at which MAb hE16 i.p. treatment effectively
reduced mortality was 5 days after viral challenge, which in
untreated animals coincided with the decline of WNV titers in
the serum and CSF and the emergence of endogenous neu-
tralizing antibody in serum. It is possible that endogenous
antibodies may have been affected by the administration of
hE16, but it is more likely that MAb hE16 provides a protec-
tive function up to day 5 that endogenously produced neutral-
izing antibody does not provide. For example, the findings of
preliminary studies with human MAbs against WNV derived
from B cells from infected patients suggest that the majority of
the antibody response is nonneutralizing and that the antibody
recognizes epitopes on domain II of the E protein (27). As a
DIII-specific potently neutralizing antibody, hE16 IgG was ef-
fective at day 5, even though endogenously produced neutral-
izing antibody emerged in serum beginning at 4 days. One
possible explanation is that the MAb hE16 IgG may cross the
blood-brain barrier more effectively than neutralizing anti-
body, which is almost exclusively of the IgM isotype, endog-
enously produced early (5). Indeed, there was a further 2-day
delay in the appearance of endogenously produced neutraliz-
ing antibody in the CSF. The detection of hE16 in neurological
tissues and CSF indicates that at least some of it crosses the
blood-brain barrier. Unfortunately, we were not able to detect
the distribution of low levels of hE16 in tissues using immu-
nohistochemical techniques (data not shown). It remains to be
determined whether the administration of hE16 directly into
the CSF could enhance the distribution of the antibody in CNS
and thus enhance the protective function. Future preclinical
studies with animals will test whether intrathecal or intraven-
tricular dosing of hE16 could extend the time of treatment
FIG. 3. Dose-response of MAb hE16 for survival of WNV-infected
hamsters and concentrations in serum. Five days after s.c. injection of
WNV (105.1 50% cell culture infectious doses), one-half log doses (100,
1.0, 0.32, 0.10, 0.032, 0.01, 0 mg/kg) of hE16 were administered i.p.
Fifteen animals were included in each group except the 1.0-mg/kg
group, which had 20 animals. On the next day, sera were obtained by
bleeding of the orbital sinuses of anesthetized hamsters and were
assayed for human IgG. (A) Percent survival plotted against hE16
dose. (B) Serum hE16 concentration plotted against hE16 dose. The
dosage of hE16 that yielded half-maximal survival (MED50), depicted
in panel A, was calculated by using a linear equation. (C) The dosage
of 0.13 mg/kg was extrapolated to derive the serum hE16 concentration
reflecting half-maximal therapeutic activity (MEC50) of 0.44 g/ml.
FIG. 4. Concentrations of MAb hE16 in serum and CSF at 7, 12,
and 30 dpi for WNV- or sham-infected hamsters treated i.p. at 5 dpi
with 32 mg/kg hE16. The animals were injected s.c. with 107.1 50% cell
culture infectious doses of WNV or were sham treated. Six animals
each were used in the WNV-infected and sham-infected groups.
Dashed line, limit of detection (0.6 g/ml).
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beyond 5 days in the hamster model. Such a route of admin-
istration is at least feasible in human patients.
In these studies with hamsters, the i.p. dose of MAb hE16
that maximally improved survival was 0.32 mg/kg or higher,
and the serum hE16 concentrations at 24 h associated with the
maximal therapeutic effect were 1.2 g/ml or higher. Based on
the linear relationship between antibody dose and serum con-
centration, the hE16 MED50 and the MEC50 in serum were
determined to be 0.13 mg/kg and 0.44 g/ml, respectively.
These data support a minimum serum target concentration for
efficacy in humans of 4.4 g/ml, which is 10-fold the MEC50.
The dose required to achieve this level in the serum of humans
may be estimated from data for palivizumab, an anti-respira-
tory syncytial virus humanized IgG1 MAb that is structurally
similar to hE16. Intravenous administration of palivizumab at
15 mg/kg produced a concentration in serum of 228 g/ml after
1 day (3); this level greatly exceeds the minimum target con-
centration in serum defined above. By using a linear relation-
ship between administered dose and concentration in serum,
hE16 doses of 0.3 mg/kg may be sufficient to produce concen-
trations in serum of approximately 4 g/ml in humans after 1
day. Assuming that hE16 has a serum half-life in humans
similar to that of palivizumab (22 days), calculations predict
that therapeutic levels of hE16 in a human subject should be
sustainable for weeks to months following the administration
of a single dose. Since the CED route is not likely to be used
for the administration of hE16 in human patients, the concen-
tration of hE16 was not determined in serum or CSF of ham-
sters that received hE16 by the CED route.
The concentration of MAb hE16 in the serum and CSF were
not statistically significantly different between WNV-infected
and sham-infected hamsters. Since other viral infections often
cause increased permeability of the blood-brain barrier (22,
28), the WNV-infected animals might have been expected to
have had higher levels of hE16 in the CSF; however, that was
not the case. The hE16 concentrations in serum also correlated
with the hE16 levels in CNS tissues, which were also similar in
uninfected and infected animals. Thus, the majority of hE16
was not sequestered or destroyed after uptake of virus-immune
complexes by phagocytic cells. Likely, after hE16-opsonized
virus entered cells, hE16 was recirculated to the extracellular
compartment after binding to the neonatal Fc receptor FcRn
(4). Thus, the serum hE16 concentration was a marker of the
concentration in other tissues of WNV-infected animals, with
the possible exception of the spinal cord. Such data may be
important in the planning of human clinical trials.
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